3
Announcements
Trials
Browse
Landscape
Status
Available
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
20
Observational
3
Expanded_access
1
Sponsor
Cancer Type
Other hematologic neoplasm
1
Myeloid
1
Conditions
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
1
Interventions
nilotinib
4
ruxolitinib
2
ponatinib
2
venetoclax
1
selinexor
1
navitoclax
1
midostaurin
1
fludarabine phosphate
1
asciminib
1
Whole-Body Irradiation
1
Transplantation
1
Tacrolimus
1
Mycophenolic Acid
1
Imatinib Mesylate
1
Dasatinib
1
Cytarabine
1
Cord Blood Stem Cell Transplantation
1
Busulfan
1
Bone Marrow Transplantation
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Expanded_access
×
asciminib
×
Myeloid
×
Clear all
NCT04360005
2025-12-05
Managed Access Programs for ABL001, Asciminib
Novartis
Available